Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology, Hematology & Immunotherapy

About MaverickNY

Here are my most recent posts

Posts by MaverickNY

What’s hot in lung cancer?

Gardens by the Bay in Singapore

With the abstract titles now available for the World Congress in Lung Cancer (WCLC), it’s time to take a look at what we can expect for the meeting coming up in early September.

In our latest conference Preview, we have highlighted several education sessions to look at, as well as ten key oral presentations to watch out for…

To continue reading our latest highlights on oncology new product development including commentary and analysis, BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Important and novel research to be inspired by

It’s time for our latest Journal Club edition for July 2023!

The good news is this volume it is full of some really good research coming out lately.

Some of these ideas may well have important therapeutic implications since these are not dusty old ideas rehashed and thrashed about.

Instead, they offer some fresh hints of emerging trends and where we might see some novel pipeline approaches coming out in due course…

When it comes to summer science reading, what’s not to like?

To continue reading our latest highlights on oncology new product development including commentary and analysis, BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Summer Shorts

The united colours of healthcare

As we continue our summer shorts series – quick looks at topics we don’t usually cover you can read in a jiffy – be aware not all of these pieces will be light hearted in nature…

A few posts will tackle some serious issues the industry is facing, requiring serious people to step up and solve them.

It’s interesting being on the other side of the fence where you can see trends and challenges more clearly than within.

There are also sides of Pharmaland I really dislike – this is one of them…

To continue reading our latest highlights on oncology new product development including commentary and analysis, BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Digging deep for answers

Imagine walking through some delightful countryside or along the coastal headlands…

Suppose you are then informed somewhere in this vicinity is a small patch – just one – of bright purple thistles in full bloom and your job is to find them as quickly and expeditiously as possible.

This is one challenge facing Pharmaland on a daily basis and while it sounds easy in theory, it often is more time consuming to answer than many may realise, including analysts chasing their colour commentary.

Today’s story explains the problem and illustrates how it might be tackled…

To continue reading our latest highlights on oncology new product development including commentary and analysis, BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Summer fun with AI

It’s the time of the year when many BSB readers will be taking time off to renew and recuperate before the hurly burly of the Fall cancer conference season begins.

This gives us a wonderful opportunity to offer some lighter fare to inspire and stimulate tired brains.

In the first example we are offering a ‘how-to’ to demonstrate what readers can do with a publicly available AI tool to make their own workflow easier and more efficient through the lens of some case examples.

Whether you are a translational scientist, oncologist, or financial analyst the examples will have some applicability to your daily lives.

After all, many of us has to write about science in some shape or form regularly, so why not make it more fun and enjoyable as well…

To continue reading our latest highlights on oncology new product development including commentary and analysis, BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Cut and run

Sometimes it’s the unexpected or quirky changes that stand out

While many observers have almost exclusively focused on protein degradation in the context of modern chemical proximity approaches, this isn’t the only possibility when using a bifunctional small molecule.

Indeed, I would argue some of the most creative ideas we are seeing coming out of late may well turn out to be unexpected standouts in future clinical trials.

Yet their goal is a very different one from what we’ve seen from the majority in the clinic.

In this latest example of the genre, we turn our attention to an area where drug hunters have struggled to find solutions for, despite the challenge being a commonplace issue for many oncologists in the clinic…

To continue reading our latest highlights on oncology new product development including commentary and analysis, BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

A window into the future of IO

Phare de Kerkmorvan depuis 1849

It’s time to shine a light – or more correctly a beacon – on a novel approach to tackling advanced tumours.

If we want to improve beyond the low hanging fruit in immuno-oncology then we need to start tackling some of the more difficult challenges.

By the way, have you ever noticed how many observers will pick up on whatever is moving – like the sailboat in the photo – while missing the bigger picture that’s been around for a lot longer right in front of them?

Sometimes this happens in cancer research too.

Today’s story is very much along on these lines where an increasing body of research is starting to add up regarding an axis many have ignored, although admittedly it’s not as old as the lighthouse.

The thing is though, it could well turn out to be more enlightening than many realise…

To continue reading our latest highlights on oncology new product development including commentary and analysis, BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Standing out from the crowd in AML

Can Nkarta stand out from the CAR-NK crowd?

Over the years we have written quite a bit about NK cell therapies and CAR-NKs in particular.

To date none have been approved, although there is certainly plenty of competition in this niche.

The latest company to showcase their emerging data on early clinical developments are Nkarta Therapeutics.

Here we take a look at their recent data on several fronts and offer insights based on what we know about the biology involved and where things might be headed in the future.

To continue reading our latest highlights on oncology new product development, including commentary and analysis, BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Next generation CAR-T cell therapies for the future

Putting new CARs in the spotlight

As we move on from second generation CAR-T cell therapies and CRISPR gene editing as well as a DNA to RNA shift, there’s a noticeable coming together of these modalities in novel next generation ideas now entering early stage trials in the clinic.

Inevitably some will fail, others will meet with mixed reactions on modest data, but a few will succeed and inspire the next round of innovative approaches.

Are there early signs of which products/companies might fall into each bucket?

Here we highlight fourteen examples to watch out for across biotechs and pharma alike while discussing some of the opportunities and challenges they may face…

To continue reading our latest highlights on oncology new product development including commentary and analysis, BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

An alternative perspective on Hodgkins lymphoma

Old town in Lugano

Oftentimes I find lymphoma clinical data presented as an encore at iCML are much more conducive to thoughtful reflection than than during the intense hurly burly of ASCO.

After all, not all phase 3 trials with a significant progression-free survival (PFS) will necessarily be subsequently adopted as the standard of care in the near-term without demonstration an overall benefit.

Lymphoma experts tend to be mindful of the risks of secondary malignancies, as well as long term side effects given the younger population they may be treating in some conditions.

In this review we take a look at some key data and explore the impact from several different perspectives…

To continue reading our latest highlights on oncology new product development including commentary and analysis, BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

error: Content is protected !!